API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://feeds.issuerdirect.com/news-release.html?newsid=6432598367320275
https://www.globenewswire.com//news-release/2024/02/20/2831850/0/en/Tenax-Therapeutics-Announces-Global-License-Amendment-that-Significantly-Expands-Rights-to-Levosimendan.html
https://www.globenewswire.com//news-release/2024/02/08/2825648/0/en/Tenax-Therapeutics-Enrolls-First-Patient-in-Phase-3-LEVEL-Study-Evaluating-TNX-103-Oral-Levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-in-Heart-Failure-with-Preserved-Eje.html
https://www.globenewswire.com//news-release/2023/11/13/2779076/0/en/Tenax-Therapeutics-Announces-FDA-Clearance-of-IND-for-TNX-103-oral-levosimendan-for-the-Treatment-of-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-H.html
https://www.globenewswire.com/news-release/2023/07/19/2707305/0/en/Tenax-Therapeutics-Issued-U-S-Patent-for-Oral-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-with-Preserved-Ejection-Fraction-PH-HFpEF.html
https://www.globenewswire.com/news-release/2023/02/01/2600032/0/en/Tenax-Granted-Notice-of-Allowance-for-U-S-Patent-Application-Covering-Use-of-IV-Levosimendan-in-Pulmonary-Hypertension-with-Heart-Failure-and-Preserved-Ejection-Fraction-PH-HFpEF.html
https://www.globenewswire.com/news-release/2022/10/10/2531000/0/en/Positive-Data-Presented-at-HFSA-Annual-Meeting-Demonstrate-Effects-of-Oral-Levosimendan-in-Patients-with-Pulmonary-Hypertension-and-Heart-Failure-with-Preserved-Ejection-Fraction-P.html
https://www.globenewswire.com/news-release/2022/01/12/2365672/0/en/Tenax-Therapeutics-Granted-U-S-Patent-for-the-Subcutaneous-Use-of-Levosimendan-TNX-102.html
https://www.biospace.com/article/releases/tenax-therapeutics-gains-north-american-rights-to-oral-levosimendan-through-expanded-license-agreement-with-orion-corporation/#:~:text=(Nasdaq%3A%20TENX)%2C%20a,develop%20and%20commercialize%20in%20the
https://www.globenewswire.com/news-release/2020/07/28/2068949/0/en/Orion-s-phase-3-REFALS-trial-evaluating-the-efficacy-of-oral-levosimendan-in-treatment-of-ALS-patients-did-not-reach-its-pre-specified-endpoints.html
https://www.businesswire.com/news/home/20190311005094/en/Tenax-Therapeutics-Enrolls-Patient-Phase-2-Pulmonary/?feedref=JjAwJuNHiystnCoBq_hl-bQQCakZDujohEJegUyaJwquReQ0P23MrIoWkrUSV24ZevRMp3sIgu8q3wq1OF24lT93qbEzrwa15HGbLqMObxbNWfZlBntHS6jpH5ROLXsTFMkl05DM8ABqeyBleEmzJA==
https://www.fiercebiotech.com/research/newly-discovered-als-mechanism-could-open-up-for-drug-development
https://www.fiercebiotech.com/orion-take-repurposed-heart-failure-drug-into-phase-3-for-als
https://www.businesswire.com/news/home/20180301005168/en/Tenax-Therapeutics-Announces-New-Scientific-Publication-Preclinical